San Francisco biotech developing drugs that activate iNKT immune cells to clear senescent cells from the body.
Clinical-stage developer of small-molecule senolytics that selectively clear pathologic senescent cells driving age-related disease.
Join to open the full comparison.
The Briefing, free for life.